Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:15 2024-09-06 am EDT 5-day change 1st Jan Change
536.20 CHF +0.52% Intraday chart for Lonza Group AG -3.49% +51.60%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Lonza Group Unit Prices EUR1.2 Billion Dual-tranche Straight Bonds MT
LONZA : Stifel raises its target price CF
LONZA GROUP : Vacaville acquisition drives Biologics’ future Alphavalue
Equita SIM Downgrades Lonza Group to Hold, Lifts PT MT
LONZA GROUP : A brighter perspective Alphavalue
Swiss Equities Close Busy Earnings Day in the Red MT
Transcript : Lonza Group AG, H1 2024 Earnings Call, Jul 25, 2024
Lonza Shares Rise After Company Backs Outlook DJ
Lonza's H1 Profit Slides 20% MT
Lonza Backs View Despite Earnings Slip DJ
Lonza Posts Lower H1 Attributable Profit, Sales MT
Lonza Group AG Confirm Sales Guidance for the Year 2024 CI
Lonza Group AG Reports Earnings Results for the Half Year Ended June 30, 2024 CI
Lonza Group Names New CEO MT
Lonza Group AG Announces CEO Changes CI
Lonza Group's New CEO Assumes Role MT
Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation MT
Swiss Market Index Edges Up Ahead of Inflation Report MT
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
Transcript : Lonza Group AG, Q1 2024 Earnings Call, May 14, 2024
Lonza Backs Guidance Despite Soft Start to Year DJ
Lonza Affirms FY24 Sales Outlook, Raises Mid-term Growth Guidance MT
Lonza Group AG Announces Board Changes CI
Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024 CI
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... Our Logo
Chart Lonza Group AG
More charts
Logo Lonza Group AG
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (55.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (17.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.4%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.4%); - other (3.5%). Net sales are distributed geographically as follows: Switzerland (17.4%), Europe (31.7%), the United States (31.8%), the Americas (3.2%), Japan (8.1%), Asia (7.5%) and other (0.3%).
Employees
17,834
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
536.20CHF
Average target price
623.67CHF
Spread / Average Target
+16.31%
Consensus
  1. Stock Market
  2. Equities
  3. LONN Stock
  4. News Lonza Group AG
  5. Lonza Group: Vacaville acquisition drives Biologics’ future
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW